BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

AlTaweel M, Alshaikh Husain M, Rashid AlSubaiee M, Al Qarni A, Aldossary I

Current medical research and opinion1 May 2026

PMID42381378DOI10.1080/03007995.2026.2692167PepBankPUB-42381378

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In Saudi adults on dapagliflozin with or without semaglutide, absolute BMI change differed across BMI classes, with the greatest reduction in obesity III.
In plain wordsIn Saudi adults on dapagliflozin with or without semaglutide, people with the highest BMI class lost the most BMI points.
Peptide
Semaglutide
Outcome
DecreaseAbsolute BMI change across BMI classes
Study
n = 328
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Absolute BMI change
−1.05 kg/m²
Obesity III
Absolute BMI change
−0.09 kg/m²
Normal
Source sentences
Summary
Absolute ΔBMI differed significantly across classes (Kruskal-Wallis, p = 0.005), with the greatest reduction in Obesity III (-1.05 vs. -0.09 kg/m² in Normal; Bonferroni p_adj = 0.017).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational cohort of 328 patients initiated on dapagliflozin ± once-weekly semaglutide at King Abdulaziz Hospital, MNGHA, Al-Ahsa (follow-up 90-365 days).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4238137801
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In Saudi adults on dapagliflozin with or without semaglutide, proportional BMI change was uniform across BMI classes.
In plain wordsIn Saudi adults on dapagliflozin with or without semaglutide, the percentage BMI change was similar across BMI classes.
Peptide
Semaglutide
Outcome
No significant changeProportional BMI change across BMI classes
Study
n = 328
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Proportional change was uniform (p = 0.182)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational cohort of 328 patients initiated on dapagliflozin ± once-weekly semaglutide at King Abdulaziz Hospital, MNGHA, Al-Ahsa (follow-up 90-365 days).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4238137802
03HumanNot a test of Semaglutide aloneObservational studyOther
In Saudi adults on dapagliflozin with or without semaglutide, baseline BMI was the dominant predictor of BMI change.
In plain wordsIn Saudi adults on dapagliflozin with or without semaglutide, a higher starting BMI went with a larger BMI drop.
Peptide
Semaglutide
Outcome
DecreaseBaseline BMI as predictor of BMI change
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Measurements
Beta coefficient
−0.38
baseline BMI
Source sentences
Summary
Baseline BMI was the dominant predictor (β = -0.38, p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational cohort of 328 patients initiated on dapagliflozin ± once-weekly semaglutide at King Abdulaziz Hospital, MNGHA, Al-Ahsa (follow-up 90-365 days).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4238137803
04HumanNot a test of Semaglutide aloneObservational studyOther
In Saudi adults on dapagliflozin with or without semaglutide, obesity III retained an independent association with BMI change.
In plain wordsIn Saudi adults on dapagliflozin with or without semaglutide, being in the highest BMI class was linked to a larger BMI drop.
Peptide
Semaglutide
Outcome
DecreaseObesity III as independent predictor of BMI change
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Measurements
Beta coefficient
−0.59
Obesity III
Source sentences
Summary
Obesity III retained independent association (β = -0.59, p = 0.021).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational cohort of 328 patients initiated on dapagliflozin ± once-weekly semaglutide at King Abdulaziz Hospital, MNGHA, Al-Ahsa (follow-up 90-365 days).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4238137804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.